BUROSUMAB-TWZA
Epidermal Nevus Syndrome
University of Alabama at Birminghammonoclonal_antibodyPhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Epidermal Nevus Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Nedometinib Albert Chiou | Phase 2 | CCC |
Burosumab Laura Tosi | Early Phase 1 | C |
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →